Compare BJ & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BJ | MDGL |
|---|---|---|
| Founded | 1984 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 11.5B |
| IPO Year | 2018 | 2005 |
| Metric | BJ | MDGL |
|---|---|---|
| Price | $102.55 | $449.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 19 |
| Target Price | $104.55 | ★ $685.78 |
| AVG Volume (30 Days) | ★ 1.7M | 253.1K |
| Earning Date | 11-20-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.50 | N/A |
| EPS | ★ 2.46 | N/A |
| Revenue | ★ $21,457,274,000.00 | $180,133,000.00 |
| Revenue This Year | $11.72 | $59.57 |
| Revenue Next Year | $5.67 | $38.84 |
| P/E Ratio | $41.91 | ★ N/A |
| Revenue Growth | ★ 4.66 | N/A |
| 52 Week Low | $83.21 | $393.61 |
| 52 Week High | $106.04 | $615.00 |
| Indicator | BJ | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 63.45 | 26.04 |
| Support Level | $89.53 | $416.21 |
| Resistance Level | $105.78 | $546.29 |
| Average True Range (ATR) | 2.88 | 16.20 |
| MACD | 0.80 | -3.93 |
| Stochastic Oscillator | 70.40 | 10.83 |
BJ's Wholesale Club, founded in 1984, operates a membership-based warehouse club model primarily along the US East Coast, with roughly 260 clubs and a growing domestic presence across 21 states. In fiscal 2025, the company generated over $21 billion in revenue. BJ's offers a value-oriented assortment skewed toward grocery, perishables, and consumables (72% of sales), general merchandise (11%), and gasoline (17%). Its business model is supported by recurring membership fee income and private-label brands such as Wellsley Farms and Berkley Jensen.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.